Multiple Sclerosis Market Therapeutics Worth $20 Billion by 2024

PUNE, India, October 27, 2015 /PRNewswire/ --

Market research titled "EpiCast Report: Multiple Sclerosis - Epidemiology Forecast to 2024" states that this multiple sclerosis therapeutics market growth, which will occur across the ten major markets of the US, France, Germany, Italy, Spain, the UK, Japan, Canada, China and India, will primarily be driven by the continued uptake of premium products and an increase in treatment rates as a result of the availability of novel alternatives.

Complete report on multiple sclerosis market epidemiology with 8 tables and 7 figures, spread across 58 pages is available at http://www.rnrmarketresearch.com/epicast-report-multiple-sclerosis-epidemiology-forecast-to-2024-market-report.html .

The value of the multiple sclerosis market therapeutics will rise slowly from $17.2 billion in 2014 to approximately $20 billion by 2024, at a Compound Annual Growth Rate (CAGR) of 1.5%. In 2014, there were a total of 909,398 diagnosed prevalent cases of MS in the 10MM, and multiple sclerosis market epidemiologists forecast that by 2024, the number of diagnosed prevalent cases of MS will grow to 942,567 cases. In 2014, there were a total of 60,535 diagnosed incident cases of MS in the 10MM, and epidemiologists forecast the number of diagnosed incident cases of MS to grow to 62,635 cases in the 10MM in 2024.

Epidemiologists forecast the diagnosed prevalent and diagnosed incident cases of MS in the 10MM from 2014-2024 using country-specific studies published in peer-reviewed journals that provided the age and sex-specific diagnosed prevalence and diagnosed incidence of MS in the respective multiple sclerosis market. The epidemiologists made sure that all the selected nationally-representative studies in the respective countries assessed the prevalence and incidence using the same study definition, thereby ensuring that the results forecast for each country are comparable. The multiple sclerosis market forecast methodology was consistent across all the 10MM to allow for a meaningful comparison among them.

Order a copy of this multiple sclerosis market therapeutics research titled EpiCast Report: Multiple Sclerosis - Epidemiology Forecast to 2024 @ http://www.rnrmarketresearch.com/contacts/purchase?rname=424802 .

The Multiple Sclerosis (MS) EpiCast Report provides an overview of the risk factors, comorbidities, and global trends for MS in the ten major multiple sclerosis market (10MM) (US, France, Germany, Italy, Spain, UK, Japan, Canada, China, and India). It includes a 10-year epidemiological forecast of the diagnosed prevalent and diagnosed incident cases of MS segmented by sex and age in these markets. This report also includes a discussion of three types of MS; relapse remitting (RRMS), primary progressive (PPMS), and secondary progressive (SPMS). The multiple sclerosis market epidemiology report is written and developed by Masters and PhD-level epidemiologists and is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 10MM.

RnRMarketResearch.com has multiple newly published and relevant research reports on multiple sclerosis drugs market that might be of interest:

Secondary Progressive Multiple Sclerosis (SPMS) - Pipeline Review, H2 2015 market research report provides comprehensive information on the therapeutic development for Secondary Progressive Multiple Sclerosis (SPMS), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Secondary Progressive Multiple Sclerosis (SPMS) and special features on late-stage and discontinued projects. Companies like AB Science SA, Biogen, Inc., Daval International Limited, Genzyme Corporation and Glialogix, Inc. along with relevant drug profiles are covered in this research available at http://www.rnrmarketresearch.com/secondary-progressive-multiple-sclerosis-spms-pipeline-review-h2-2015-market-report.html .

About Us:  

RnRMarketResearch.com is your single source for all market research needs. Our database includes 500,000+ market research reports from over 100+ leading global publishers & in-depth market research studies of over 5000 micro markets. With comprehensive information about the publishers and the industries for which they publish market research reports, we help you in your purchase decision by mapping your information needs with our huge collection of reports.

Connect with Us: 

G+ / Google Plus: https://plus.google.com/104156468549256253075/posts

Twitter: https://twitter.com/RnRMR

Facebook: https://www.facebook.com/pages/RnR-Market-Research/413488545356345

RSS / Feeds: http://www.rnrmarketresearch.com/feed

Contact:
Ritesh Tiwari
UNIT no 802, Tower no. 7, SEZ
Magarpatta city, Hadapsar
Pune - 411013
Maharashtra, India.
Tel:  +1-888-391-5441
[email protected]